Navigation Links
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
Date:5/8/2013

arch 31, 2013 and December 31, 2012; noshares issued and outstanding atMarch 31, 2013 and December 31, 2012--Common stock, $.001 par value, 300,000,000shares authorized at March 31, 2013 andDecember 31, 2012 and;92,641,567 and 84,413,670 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively

9384Additional paid-in capital 

514,678512,174Accumulated other comprehensive income (loss)

1315Accumulated deficit

(456,172)(436,804)Total stockholders' equity 

58,61275,469Total liabilities and stockholders' equity 

$
,738$
39,154 

 

 

Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended March 31, 20132012Revenues:Collaborative agreement $

857$

857License revenue 00Total revenues 857857Operating expenses:Research and development 15,1556,800General and administrative 5,1004,512Total operating expenses 20,25511,312Loss from operations (19,398)(10,455)Other income (expense):Interest income 3143Interest expense and other(1)(2)Total other income (expense) 3041Net loss $

(19,368)$

(10,414)Net loss per share - basic and diluted $

(0.21)$

(0.16)Shares used in computing net loss per share – basic and diluted 90,33665,989 

 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... -- Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... River Systems announces,the successful development and operation of ... the development of its Monarch250(TM) proton,therapy system. This ... that cyclotrons at this high field strength can ... increasing the operating,magnetic field, Still River Systems is ...
... May 21 Prime Therapeutics (Prime), a,thought ... that it has,received accreditation from the National ... Verified Internet Pharmacy Practice,Sites(TM) (VIPPS(R)) Program., ... by NABP in response to,consumers, concerns regarding ...
... Aton Pharma, Inc., a global,specialty pharmaceutical company, ... distribution agreement with PharmaLink Asia Pacific Pte. Ltd.,to ... in Asia and,Australia., "This partnership marks an ... to expand access to our medically essential portfolio ...
Cached Biology Technology:Still River Systems Announces Operation of the World's Highest Magnetic Field Cyclotron 2Prime Therapeutics Receives VIPPS Accreditation 2Aton Pharma Announces Distribution Partnership in the Asia Pacific Region 2
(Date:7/11/2014)... hippocampus, the marginal division of the striatum is ... the impact degree of substance P in the ... Yan Yu and his team, College of Biophotonics, ... staining, that substance P receptor, neurokinin 1 was ... division of normal rats. Unilateral or bilateral injection ...
(Date:7/11/2014)... that let nerve cells send out electrical signals, Johns ... tactic that may offer a new way to protect ... responsible way. , Their findingthat naturally occurring insect ... for a closely related onesuggests that insecticides can be ... like bees. A summary of the research, led by ...
(Date:7/10/2014)... 27, 2014  Pomerantz LLP has filed a ... or the "Company")(NYSE-MKT: PVCT) and certain of its ... District Court, Middle District of Tennessee ... a class consisting of all persons or entities ... December 17, 2013 and May 22, 2014, both ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... Ore. The northern spotted owl, a threatened species ... long run from active management of the forest lands ... to stand-replacing fire, researchers conclude in a recent study. ... thinning, or other fuel reduction activities in areas with ...
... gas could become an important source of renewable energy, ... Researchers at both campuses are raising colonies of ... turn electrical energy into pure methane the key ... create large microbial factories that will transform clean electricity ...
... sciences have become especially data-intensive. As researchers rely ... than observations to collect data, discovering, integrating and ... to researchers, ability to address complex questions about ... in it. On March 29, 2012, President ...
Cached Biology News:Active forest management to reduce fire could help protect northern spotted owl 2Stanford-Penn State scientists use microbes to make 'clean' methane 2Stanford-Penn State scientists use microbes to make 'clean' methane 3Stanford-Penn State scientists use microbes to make 'clean' methane 4DataONE answers the call for new tools to study the Earth in this era of Big Data science 2
Multidrop Micro high speed 1 l bulk reagent dispenser rapidly, precisely and accurately dispenses microvolumes of 1-50 l into 384- and 96-well microplates....
...
...
Buckets for tube holder inserts...
Biology Products: